COR · Cencora Inc.
AI read · Good for COR
The AI's read
COR beat Q3 estimates on both EPS ($4.48 vs $4.35) and revenue ($84.754B vs $84.315B), driven by specialty volumes and distribution strength. Management raised FY26 EPS guidance and OneOncology helped lift gross profit and operating income. Shares are up about 3.5% so the market likes the print but the name is not stretched, RSI 54.43. The guidance bump plus a 24.1% jump in gross profit give the upside some credibility. Our take is lean bullish. The main downside is margin pressure from GLP-1 mix and manufacturer pricing that could cap EPS expansion if persistent.